Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Antiva Biosciences, a US-based developer of treatments for human papillomavirus spun out of University of California, San Diego, has secured $31m in a series D round backed by Osage University Partners. The round included internet and technology group Alphabet and pharmaceutical firms EMS and Dong-A, the first two through GV and Brace Pharma Capital respectively. The round was led by Adjuvant Capital and also featured Alexandria Venture Investments, HBM Healthcare Investments, Avestria Ventures, Gaingels, Mana Ventures, Canaan Partners, Sofinnova Ventures, Lumira Ventures and Sirona Capital. The company had raised a total of $57m as of its $15m series C1 round in 2018.
PierianDx, US-based clinical genomics data producer based on research at Washington University in St Louis, has raised $30m from investors including healthcare provider Inova Health System. OrbiMed led the round, which included research institute RTI, Health Catalyst Capital, ATW Partners and SJF Ventures, all four of which…
